Sandbox/Anticoagulation Strategy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 3: Line 3:


==Anticoagulation Strategy==
==Anticoagulation Strategy==
Shown below is an algorithm depicting the assessment of risk of stroke and the appropriate anticoagulation therapy among patients with AF.<ref name="pmid24685668">{{cite journal| author=January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE et al.| title=2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. | journal=J Am Coll Cardiol | year= 2014 | volume=  | issue=  | pages=  | pmid=24685668 | doi=10.1016/j.jacc.2014.03.021 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24685668  }} </ref>
Shown below is an algorithm depicting the assessment of risk of [[stroke]] and the appropriate [[anticoagulation]] therapy among patients with [[AF]].<ref name="pmid24685668">{{cite journal| author=January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE et al.| title=2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. | journal=J Am Coll Cardiol | year= 2014 | volume=  | issue=  | pages=  | pmid=24685668 | doi=10.1016/j.jacc.2014.03.021 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24685668  }} </ref>


<span style="font-size:85%">'''Abbreviations:''' '''AF''': Atrial fibrillation; '''INR''': International normalized ratio</span> <br>
<span style="font-size:85%">'''Abbreviations:''' '''AF''': Atrial fibrillation; '''INR''': International normalized ratio</span> <br>

Revision as of 02:33, 5 May 2014

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Mugilan Poongkunran M.B.B.S [2]

Anticoagulation Strategy

Shown below is an algorithm depicting the assessment of risk of stroke and the appropriate anticoagulation therapy among patients with AF.[1]

Abbreviations: AF: Atrial fibrillation; INR: International normalized ratio

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assess the absolute and relative risk of bleeding before initiating long term anticoagulation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Non-valvular AF
 
 
 
 
 
AF with valvular heart disease
 
 
 
 
 
AF with mechanical heart valves
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assess CHA2DS2-VASc scoring risk
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Score 0
 
Score 1
 
Score ≥ 2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No antithrombotic therapy
 
No antithrombotic therapy or may consider an oral anticoagulant or aspirin
 
Oral antithrombotic therapy:

Warfarin:

❑ Target INR 2-3
INR determined weekly before stabilization
 
Oral antithrombotic therapy:

Warfarin:

❑ Target INR 2-3
INR determined weekly before stabilization
 
 
 
 
 
Oral antithrombotic therapy:

Warfarin:

❑ Target INR 2-3 or 2.5-3.5 based on type and location of valve

Caution:

❑ Dont use direct thrombin inhibitor and dabigatran
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Does the patients INR stabilize to the recommended value
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
No
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Determine INR every month
 
Direct thrombin or factor Xa inhibitor:

Dabigatran, rivaroxaban, or apixaban:

❑ Evaluate renal function before initiation

Caution:

❑ Dont use in patients with end-stage CKD or on hemodialysis
 
 
 
 
 
Determine INR weekly before stabilization and then every month
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

CHA2DS2-VASc Scoring System

CHA2DS2-VASc
Variable Score
Age ≥75 years 1
Age 65-74 years 1
Female sex 1
Diabetes mellitus 1
Hypertension 1
Congestive heart failure 1
Stroke/TIA/Thromboembolism 2
Vascular disease (prior MI, PAD, or aortic plaque) 1

References

  1. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE; et al. (2014). "2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society". J Am Coll Cardiol. doi:10.1016/j.jacc.2014.03.021. PMID 24685668.


Template:WikiDoc Sources